MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Wednesday reported a loss of $9.4 million in its first quarter.
On a per-share basis, the Mountain View, California-based company said it had a loss of 19 cents.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.
The biopharmaceutical company posted revenue of $9.5 million in the period.
ChemoCentryx shares have increased 88 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $11.21, a climb of 59 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI